Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 1

Status

Active not recruiting 4Completed 3

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Neoplasm Metastasis 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1

Interventions

Carboplatin 18Cisplatin 14pembrolizumab 13durvalumab 11Pemetrexed 11Paclitaxel 11Nivolumab 11Gemcitabine 11Rituximab 9trastuzumab deruxtecan 7osimertinib 6olaparib 6Dexamethasone 6Capecitabine 6atezolizumab 5acalabrutinib 5Specimen Handling 5Lenalidomide 5Bevacizumab 5130-nm albumin-bound paclitaxel 5tremelimumab 4niraparib 4cabozantinib 4amivantamab 4Prednisone 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Has announcements × Fulvestrant × Clear all
NCT04305496 2026-04-30

CAPItello-291

AstraZeneca

Phase 3 Active not recruiting
818 enrolled 19 charts 2 FDA
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05654623 2026-03-18

VERITAC-2

Pfizer

Phase 3 Active not recruiting
624 enrolled 17 charts 1 FDA
Breast

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

Hoffmann-La Roche

Phase 2/3 Active not recruiting
325 enrolled 14 charts 1 FDA
Breast

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡